Dayvigo (Lemborexant) and Levothyroxine Interaction

Why This Combination Comes Up So Often

Hypothyroidism and insomnia overlap in roughly 10-15% of adults with thyroid disease, making this a common clinical question. In the 2019 NHANES analysis, approximately 12.1% of Americans aged 12 and older were taking levothyroxine, making it the most prescribed medication in the United States by volume [1]. Sleep disturbance is a recognized symptom of both undertreated and overtreated hypothyroidism, as documented in the American Thyroid Association (ATA) 2014 guidelines for the treatment of hypothyroidism [2].

Lemborexant received FDA approval in December 2019 for the treatment of insomnia characterized by difficulty with sleep onset and/or sleep maintenance [3]. As a dual orexin receptor antagonist, it works differently from older sedative-hypnotics. Prescribers and patients both need clarity on whether these two daily medications interact.

The short answer: they do not share metabolic enzymes or transporters that would produce a clinically meaningful pharmacokinetic interaction. The real concern is timing.

Pharmacokinetic Profiles: Two Drugs, Two Separate Pathways

Understanding why this combination is safe requires a look at how each drug moves through the body. Lemborexant is absorbed orally with a T-max of approximately 1 to 3 hours, is highly protein-bound (94%), and undergoes hepatic metabolism primarily via CYP3A4 with minor contributions from CYP3A5 [3]. Its half-life is approximately 17 to 19 hours, which informs its once-nightly dosing.

Levothyroxine follows a completely different route. It is absorbed primarily in the jejunum and upper ileum, with a bioavailability of 40-80% that is highly dependent on gastric pH and the absence of food or interfering substances [4]. Levothyroxine does not undergo CYP-mediated hepatic metabolism. Instead, it is converted to the active hormone triiodothyronine (T3) through peripheral deiodination by type 1 and type 2 deiodinase enzymes [5].

Because lemborexant is metabolized by CYP3A4 and levothyroxine bypasses the cytochrome P450 system entirely, there is no enzymatic competition between these two drugs. The FDA label for Dayvigo lists CYP3A4 inhibitors and inducers as clinically relevant interacting agents (e.g., itraconazole, rifampin) but does not list levothyroxine [3]. The Synthroid prescribing information lists drugs that impair T4 absorption (calcium carbonate, ferrous sulfate, proton pump inhibitors) but does not mention orexin receptor antagonists [4].

The Absorption Window: The Only Practical Concern

While no direct drug-drug interaction exists, levothyroxine's finicky absorption profile creates a timing consideration with any coadministered medication. A 2017 study in Thyroid (N=45) demonstrated that taking levothyroxine with coffee reduced T4 absorption by approximately 36% compared to taking it with water alone on an empty stomach [6]. The ATA recommends taking levothyroxine on an empty stomach, 30 to 60 minutes before breakfast, or alternatively at bedtime at least 3 hours after the last meal [2].

This is where timing logistics matter. Patients taking Dayvigo at bedtime may also consider bedtime dosing of levothyroxine. A 2012 randomized crossover trial published in the Archives of Internal Medicine (N=90) found that bedtime administration of levothyroxine actually produced lower TSH levels and higher free T4 levels compared to morning dosing, suggesting bedtime administration is a viable alternative [7]. If a patient takes levothyroxine at bedtime, the dose should be administered at least 3 hours after dinner, and Dayvigo can be taken at the same time since it does not interfere with T4 absorption through pH changes, chelation, or adsorption.

For patients who prefer morning levothyroxine dosing, the separation from Dayvigo is already built in. Dayvigo is taken at night immediately before bed. By morning, 8 or more hours have elapsed. No additional spacing adjustments are needed.

CYP3A4 Interactions That Actually Matter for Dayvigo

While levothyroxine is not a concern, several other medications do require dose modifications when combined with lemborexant. The FDA label specifies the following [3]:

Strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin, ketoconazole) are contraindicated with Dayvigo. In a pharmacokinetic study, coadministration with itraconazole increased lemborexant AUC by approximately 4-fold [3].

Moderate CYP3A4 inhibitors (e.g., fluconazole, erythromycin, verapamil, diltiazem) require a dose reduction of Dayvigo to no more than 5 mg nightly [3]. Weak CYP3A4 inhibitors do not require dose adjustment.

Strong and moderate CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin) significantly reduce lemborexant exposure and may diminish efficacy. The Dayvigo label recommends against concomitant use with strong CYP3A4 inducers and advises monitoring for reduced effectiveness with moderate inducers [3].

Dr. Andrew Krystal, professor of psychiatry at the University of California San Francisco and a lead investigator in the SUNRISE clinical trials, noted in a 2020 review: "The CYP3A4-dependent metabolism of lemborexant means clinicians must screen for azole antifungals and macrolide antibiotics before prescribing, but thyroid hormones and most endocrine medications do not pose interaction risks" [8].

Drugs That Actually Interfere With Levothyroxine

For patients on levothyroxine, the interaction watchlist is long and well-characterized. These are the medications and supplements that require spacing of at least 4 hours from levothyroxine [4][9]:

Calcium carbonate reduces levothyroxine absorption by 25% when taken simultaneously, per a study in the Journal of Clinical Endocrinology and Metabolism (N=20) [10]. Ferrous sulfate decreases T4 absorption by approximately 33-60% depending on the formulation [11]. Aluminum-containing antacids, sucralfate, and bile acid sequestrants (cholestyramine, colesevelam) also bind T4 in the gut.

Proton pump inhibitors such as omeprazole reduce gastric acidity, which impairs the dissolution of levothyroxine tablets. A 2006 study in the Journal of Clinical Endocrinology and Metabolism showed that patients on PPIs required a mean levothyroxine dose increase of 37% to maintain target TSH [12].

Lemborexant does not chelate minerals, alter gastric pH, or bind bile acids. It has no known mechanism to impair levothyroxine absorption.

Hypothyroidism, Insomnia, and the Clinical Overlap

The relationship between thyroid function and sleep architecture is bidirectional and well-documented. A 2021 meta-analysis published in BMC Endocrine Disorders (12 studies, N=36,213) reported that the prevalence of sleep disturbance in hypothyroid patients was 46.2%, compared to 27.1% in euthyroid controls [13]. Sleep complaints in hypothyroidism include difficulty initiating sleep, frequent awakenings, and nonrestorative sleep.

Before attributing insomnia to a primary sleep disorder, clinicians should confirm that TSH is at goal. The ATA 2014 guidelines recommend a TSH target of 0.45-4.12 mIU/L for most adults, though individual symptomatic targets may vary [2]. Overtreated patients with suppressed TSH (<0.1 mIU/L) may experience insomnia from iatrogenic subclinical hyperthyroidism.

Dr. Elizabeth Pearce, former president of the American Thyroid Association, stated in a 2023 Endocrine Society clinical update: "Persistent sleep complaints in patients on levothyroxine should prompt a TSH recheck, but once thyroid status is optimized, primary insomnia treatment including DORAs like lemborexant is appropriate" [14].

Once thyroid replacement is optimized and insomnia persists, lemborexant is a reasonable pharmacologic option. The SUNRISE-2 trial (N=949), a 12-month phase III study, demonstrated that lemborexant 5 mg and 10 mg significantly improved subjective sleep onset latency (sSOL) and subjective wake after sleep onset (sWASO) compared to placebo through 6 months, with sustained benefits through 12 months of open-label treatment [15].

Monitoring When Using Both Medications

No special monitoring is required specifically for the combination. Standard practice for each drug individually applies.

For levothyroxine: check TSH 6 to 8 weeks after initiation, dose change, or addition of any new interacting medication. Annual TSH monitoring is appropriate once stable [2]. If a patient reports new fatigue, weight gain, or cold intolerance after starting Dayvigo, recheck TSH to rule out unrelated thyroid dose drift, though Dayvigo itself is not expected to alter thyroid levels.

For lemborexant: assess for next-day somnolence, which occurred in 7% of patients on lemborexant 10 mg vs. 1% on placebo in SUNRISE-1 [16]. Monitor for complex sleep behaviors (sleepwalking, sleep-driving), which carry an FDA boxed warning for all orexin receptor antagonists [3]. Evaluate for worsening depression or suicidal ideation, particularly in patients with comorbid mood disorders.

Hepatic impairment affects lemborexant dosing. In patients with moderate hepatic impairment (Child-Pugh B), the maximum recommended dose is 5 mg [3]. Severe hepatic impairment (Child-Pugh C) has not been studied and Dayvigo is not recommended in this population.

Practical Dosing Schedule for Patients on Both Drugs

The simplest approach separates the two drugs by the patient's natural sleep-wake cycle.

Morning levothyroxine protocol: Take levothyroxine immediately upon waking with a full glass of water. Wait 30 to 60 minutes before eating, drinking coffee, or taking other medications. Take Dayvigo 5 or 10 mg at bedtime, immediately before attempting to sleep. The two drugs are separated by approximately 15 to 17 hours. No interaction risk.

Bedtime levothyroxine protocol: Eat dinner at least 3 hours before the planned levothyroxine dose. Take levothyroxine with water. Take Dayvigo immediately before lying down. Both drugs can be taken within the same 30-minute bedtime window because lemborexant does not interfere with T4 absorption mechanisms [3][4].

Patients should avoid taking levothyroxine with calcium supplements, iron supplements, or antacids within 4 hours [9]. This spacing rule applies regardless of whether Dayvigo is part of the regimen.

Special Populations

Elderly patients (age 65 and older) represent a population where both medications are frequently prescribed. The SUNRISE-1 trial included patients aged 55 and older (N=291 in the elderly subgroup), and lemborexant 5 mg demonstrated significant improvement in sleep efficiency (SE) measured by polysomnography: 86.4% vs. 81.2% for placebo at 1 month [16].

For elderly patients on levothyroxine, the ATA recommends a lower starting dose (25 to 50 mcg daily) with gradual titration, particularly in patients with coronary artery disease [2]. There is no age-specific interaction concern when combining the two drugs, though elderly patients are more sensitive to both residual sedation from Dayvigo and cardiovascular effects from levothyroxine dose changes.

Pregnant patients should note that lemborexant is classified as not recommended during pregnancy due to insufficient human data [3]. Levothyroxine requirements typically increase by 25-50% during pregnancy, requiring TSH monitoring every 4 weeks through mid-gestation [17].

When to Involve the Prescriber

Patients should contact their clinician if they experience symptoms of thyroid level changes (new fatigue, palpitations, unintended weight changes, heat or cold intolerance) after starting Dayvigo, although the medication is not expected to cause these effects. Any episode of complex sleep behavior (sleepwalking, sleep-eating, sleep-driving) warrants immediate discontinuation of Dayvigo and medical evaluation [3]. Patients using moderate CYP3A4 inhibitors for other conditions (e.g., diltiazem for hypertension, fluconazole for fungal infection) should alert their prescriber, as these require a Dayvigo dose cap of 5 mg nightly [3].

The TSH recheck interval after starting Dayvigo should follow the standard 6 to 8 week protocol used for any new concomitant medication, even in the absence of a known interaction, to rule out coincidental thyroid level drift [2].